Atombeat Accelerates AI-Driven Drug Discovery Efforts
Published on 8.1.25
Atombeat's platform accelerates AI-driven drug discovery by leveraging its proprietary Hermite software and RiDYMO platform to explore a vast digital library of over one trillion potential peptide compounds. The platform uses advanced computer modeling, artificial intelligence, and specialized data to rapidly filter and prioritize compounds based on developability traits such as membrane permeability, saving time, cost, and effort in the early stages of drug discovery.